Updated results shows SC trastuzumab as safe and effective as IV formulation

Share this content:

the ONA take:

According to updated results of the HannaH study published in the journal Annals of Oncology, researchers have found that subcutaneous trastuzumab has a similar safety profile and similar event-free survival rate with intravenous trastuzumab. For the phase 3 study, researchers enrolled 596 patients with human epidermal growth factor receptor 2 (HER2)-positive, operable, locally advanced, or inflammatory breast cancer and assigned them to receive neoadjuvant chemotherapy for eight cycles with either trastuzumab 600mg subcutaneously every 3 weeks or standard weight-based intravenous trastuzumab every 3 weeks. Patients received trastuzumab for 1 year.

Results showed that the incidence of adverse events, including serious adverse events, were similar in both treatment groups; however, there was a slightly increased incidence of infections in the subcutaneous arm. The researchers also conducted an early analysis of efficacy and found that the event-free survival rates were 95% in both groups at 1 year following randomization. Exploratory analyses found no association between body weight or exposure and toxicity.

Trasuzumab is a HER2/neu receptor antagonist approved by the U.S. Food and Drug Administration for the treatment of HER2 over expressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma by intravenous infusion only.

Updated results shows SC trastuzumab as safe and effective as IV formulation
Updated results shows SC trastuzumab as safe and effective as IV formulation
According to the results of the present study, the safety profile of subcutaneous (s.c.) trastuzumab was consistent with the previously published data from HannaH and the known safety profile of intravenous (i.v.) trastuzumab.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs